FDA’s Preliminary Review of GLP-1 Meds Finds No Tie to Suicidal Thoughts, Actions

The FDA has found no evidence that GLP-1 drugs used for diabetes and weight loss cause suicidal thoughts or actions. Reports in the FDA Adverse Event Reporting System prompted the review, but the agency determined that the reports did not demonstrate a clear relationship with GLP-1 drugs. However, the agency will continue to look into the issue due to the small number of suicidal thoughts or actions observed. GLP-1 drugs are used initially as treatments for type 2 diabetes, but have been approved for weight management. The most common side effects are gastrointestinal problems, and there is concern about a potential association between GLP-1 drugs and suicide.

Source link